(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 199.79% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Cytokinetics's revenue in 2025 is $18,474,000.On average, 11 Wall Street analysts forecast CYTK's revenue for 2025 to be $3,327,458,772, with the lowest CYTK revenue forecast at $473,642,756, and the highest CYTK revenue forecast at $10,692,485,217. On average, 10 Wall Street analysts forecast CYTK's revenue for 2026 to be $27,522,670,087, with the lowest CYTK revenue forecast at $13,901,414,889, and the highest CYTK revenue forecast at $46,890,632,844.
In 2027, CYTK is forecast to generate $60,570,619,744 in revenue, with the lowest revenue forecast at $41,171,396,565 and the highest revenue forecast at $93,319,464,001.